Ritalin (Methylphenidate HCl) Patent Expiration, LOE Window & CMS Spending

Ritalin (Methylphenidate HCl) by Sandoz: Off-Patent Genericized (AB Competition), 12 AB generics, $964K 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSandoz
FDA Application & PathwayN010187 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$964K
2024 Medicare Part D Spend$720K
2024 Medicaid Spend$243K
Reported Wholesale Price Change (CA SB 17)7 WAC filings (max 26.8% 2-yr change)